The blood clotting cascade may offer unexpected leverage against one of medicine's most lethal malignancies. Pancreatic ductal adenocarcinoma kills nearly all patients within five years, partly because its dense fibrous environment shields cancer cells from immune attack and facilitates spread to distant organs.
This research demonstrates that deliberately depleting fibrinogen—a key clotting protein chronically elevated in pancreatic cancer patients—substantially reduces both primary tumor growth and metastatic spread in patient-derived xenograft models. The intervention used clinically-relevant antisense oligonucleotides and lipid nanoparticle delivery systems already in human trials for other conditions. Fibrinogen depletion triggered cascading changes in the tumor's protein landscape, reducing serine protease activity essential for tissue remodeling and cancer cell migration. Spatial analysis revealed that treated tumors accumulated more cancer-restraining fibroblasts, suggesting the intervention fundamentally reorganizes the supportive tissue architecture that normally enables aggressive growth.
This finding challenges the assumption that targeting blood clotting mechanisms primarily benefits cardiovascular disease. The coagulation system's role in cancer progression has been underexplored therapeutically, despite decades of observational evidence linking elevated clotting factors to poor cancer outcomes. The study's strength lies in using patient-derived models rather than laboratory cell lines, improving clinical relevance. However, the work remains preclinical, and fibrinogen's normal hemostatic functions could complicate therapeutic applications. Still, repurposing existing antisense technologies for cancer treatment represents a potentially faster path to clinical testing than developing entirely novel compounds.